Search Results

Nanite, Inc. and SalioGen Therapeutics announced a research collaboration that will utilize Nanite’s SAYER™ delivery platform to develop a lung-targeting polymer nanoparticle designed to integrate the cystic fibrosis transmembrane conductance regulator gene directly into lung cells using SalioGen’s novel Gene Coding™ technology.

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company’s camonsertib monotherapy non-small cell lung cancer (NSCLC) expansion of the TRESR clinical trial.

Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN) today announced it has acquired Lung Therapeutics, Inc. (“Lung Tx”).

Aerami Therapeutics announced the presentation of new lung deposition modeling data for AER-901 at the American Thoracic Society 2024 International Conference being held May 17-22, 2024, in San Diego, California.

Abdera Therapeutics Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ABD-147 for the treatment of patients with extensive stage small cell lung cancer (ES-SCLC) who have progressed on or after platinum-based chemotherapy.

The small cell lung cancer therapeutics market size was valued at 5.75 billion in 2023 and is anticipated to reach around 16.33 billion by 2032, expanding at a CAGR of 12.3% from 2023 to 2032.